Nureca Limited has informed the Outcome of Board Meeting held on 29th May,2026.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Limited's Board approved audited financial results for Q4 and FY26 (standalone and consolidated). Full-year revenue grew 28.4% to ₹1,472.10 million from ₹1,146.40 million in FY25. The company returned to profitability with PAT of ₹2.97 million versus a loss of ₹6.68 million in FY25. However, Q4 alone showed a loss of ₹66.25 million. An exceptional loss of ₹83.37 million was recorded due to fair value changes on investments. The Board approved ₹100 crore capex for manufacturing expansion of medical devices and healthcare products at Derabassi, Punjab, plus land purchase for future expansion. CFO Mr. Naresh Gupta resigned effective June 26, 2026, and Mr. Chander Kant was promoted from Manager Finance to CFO effective June 27, 2026. Three director re-appointments (Aryan Goyal, Saurabh Goyal, Smita Goyal) were approved, all subject to shareholder approval at the July 28, 2026 AGM. The auditors issued an unmodified (clean) opinion.
Revenue growth of 28.4% demonstrates strong business momentum, though Q4 loss and exceptional investment loss of ₹83.37 million raise concerns about profitability sustainability. The leadership changes and capex expansion signal growth ambitions, but investors should monitor Q4 loss drivers and related party concentrations given the family-run board structure.